Aug 14, 2023
The positive interim Phase II data with LTX-315 from Verrica Pharmaceuticals Inc. (Lytix Biopharma’s licensing partner) stirs attention

Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc (“Verrica”) reported lesion clearance data from Part 1 of an ongoing Phase II study of VP-315 (formerly known as LTX-315) for the treatment of basal cell carcinoma (BCC). Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with BCC.

The results were orally presented at the 2023 American Academy of Dermatology Innovation Academy meeting, August 10-13, in Tampa, Florida, and the data stirs attention.


Among the articles, check: